The product candidates are protected by several international patents. The current patent portfolio comprises two patent families. Patent family 1 (TCP-25/P7834) comprises a US patent and an EP patent (in force in Germany, France, the UK and Switzerland/Lichtenstein) claiming the TCP-25 peptide and variants as well as products comprising these peptides and methods of using the peptides. Patent family 2 (TCP-25/10144) also comprises a US patent and an EP patent and claims the medical use of a peptide comprising or consisting of the TCP-25 peptide for use in treating various coagulative disorders, and additionally inflammation. A patent application on TCP-25 formulations has recently been filed. The IP-strategy includes to further extend the patent portfolio geographically and temporally.